Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Dejan Z. Aleksić, Miloš N. Milosavljević, Srđan M. Stefanović, Andriana Bukonjić, Jovana Z. Milosavljević, Slobodan M. Janković, Ivo Božović, Stojan Perić & Dragana Lavrnić. (2021) Risk factors for potential drug–drug interactions in patients with myasthenia gravis. Neurological Research 43:12, pages 1023-1030.
Read now
Read now
Amelia Evoli, Raffaele Iorio & Emanuela Bartoccioni. (2016) Overcoming challenges in the diagnosis and treatment of myasthenia gravis. Expert Review of Clinical Immunology 12:2, pages 157-168.
Read now
Read now
Articles from other publishers (13)
Ying Tan, Jiayu Shi, Yangyu Huang, Ke Li, Jingwen Yan, Li Zhu, Yuzhou Guan & Liying Cui. (2022) Long-Term Efficacy of Non-steroid Immunosuppressive Agents in Anti-Muscle-Specific Kinase Positive Myasthenia Gravis Patients: A Prospective Study. Frontiers in Neurology 13.
Crossref
Crossref
Sivakumar Sathasivam & Andrew J. Larner. 2022. Pathy's Principles and Practice of Geriatric Medicine. Pathy's Principles and Practice of Geriatric Medicine
709
717
.
Fiammetta Vanoli & Renato Mantegazza. (2022) Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management. Neurotherapeutics 19:3, pages 897-910.
Crossref
Crossref
Thomas Mathew, Kurian Thomas, Saji K John, Shruthi Venkatesh, Raghunandan Nadig, Sagar Badachi, Delon D Souza, GRK Sarma & Gareth J Parry. (2021) Effective Early Treatment of AChR Antibody-Positive Myasthenia Gravis with Rituximab; the Experience from a Neuroimmunology Clinic in a Developing Country. Journal of Central Nervous System Disease 13, pages 117957352110160.
Crossref
Crossref
Richard J. Nowak, Srikanth Muppidi, Said R. Beydoun, Fanny L. O'Brien, Marcus Yountz & James F. HowardJr.Jr.. (2020) Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study. Frontiers in Neurology 11.
Crossref
Crossref
Przemysław Koźmiński, Paweł Krzysztof Halik, Raphael Chesori & Ewa Gniazdowska. (2020) Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers. International Journal of Molecular Sciences 21:10, pages 3483.
Crossref
Crossref
Nils Erik Gilhus, Socrates Tzartos, Amelia Evoli, Jacqueline Palace, Ted M. Burns & Jan J. G. M. Verschuuren. (2019) Myasthenia gravis. Nature Reviews Disease Primers 5:1.
Crossref
Crossref
Asger Frost, Marie Louise Svendsen, Jes Rahbek, Christina Malmose Stapelfeldt, Claus Vinther Nielsen & Thomas Lund. (2016) Labour market participation and sick leave among patients diagnosed with myasthenia gravis in Denmark 1997–2011: a Danish nationwide cohort study. BMC Neurology 16:1.
Crossref
Crossref
Amelia Evoli & Raffaele Iorio. 2016. Acquired Neuromuscular Disorders. Acquired Neuromuscular Disorders
123
135
.
M.A. Hellmann, R. Mosberg-Galili, I. Lotan & I. Steiner. (2014) Maintenance IVIg therapy in myasthenia gravis does not affect disease activity. Journal of the Neurological Sciences 338:1-2, pages 39-42.
Crossref
Crossref
J. C. Patel, M. J. Barvaliya, T. K. Patel & C. B. Tripathi. (2013) Neuromuscular blocking effect of fluoxetine and its interaction with rocuronium. Autonomic and Autacoid Pharmacology 33:1-2, pages 17-24.
Crossref
Crossref
Tyler B. Tarr, Guillermo Valdomir, Mary Liang, Peter Wipf & Stephen D. Meriney. (2012) New calcium channel agonists as potential therapeutics in Lambert-Eaton myasthenic syndrome and other neuromuscular diseases. Annals of the New York Academy of Sciences 1275:1, pages 85-91.
Crossref
Crossref
Espen Benjaminsen, Gunnar Skjeflo, Knut Dybwik & Rolf Salvesen. (2012) En mann i 70-årene med langvarig myastenisk krise. Tidsskrift for Den norske legeforening 132:19, pages 2182-2185.
Crossref
Crossref